Ste­fan Fraenkel takes over as chief of In­cep­tua Group; Christi Shaw has a plan to make Yescar­ta safer

→ Af­ter its sub­sidiary In­cep­tua Med­i­cines Ac­cess inked a deal with On­cono­va Ther­a­peu­tics to make avail­able in­tra­venous rigosert­ib via a pre-ap­proval ac­cess pro­gram in se­lect­ed coun­tries across the world, In­cep­tua Group has tapped Ste­fan Fraenkel to head the com­pa­ny’s op­er­a­tions as CEO. Fraenkel, cur­rent­ly EVP of the com­pa­ny’s busi­ness unit In­cep­tua Phar­ma, will suc­ceed Alan Raf­fensperg­er — who is mov­ing to the po­si­tion of ex­ec­u­tive vice-chair­man of the group. Fraenkel joined the com­pa­ny in 2017 and holds ex­pe­ri­ence from his pre­vi­ous roles at Wyeth Phar­ma­ceu­ti­cals and So­bi.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.